切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2013, Vol. 07 ›› Issue (04) : 289 -294. doi: 10.3877/cma.j.issn.1674-0793.2013.04.011

所属专题: 文献

论著

不同亚型乳腺癌初次转移时间及带瘤生存的研究
崔世恩1, 凌飞海1,(), 储兵2   
  1. 1. 528400 中山市人民医院乳腺外科
    2. 528400 中山市人民医院病理科
  • 收稿日期:2013-02-21 出版日期:2013-08-01
  • 通信作者: 凌飞海

Studies on the distant relapse-free survival after relapse of different subtypes of breast cancer

Shi-en CUI1, Fei-hai LING1,(), Bing CHU2   

  1. 1. Department of Breast Surgery, Zhongshan City People's Hospital, Zhongshan 528403, China
  • Received:2013-02-21 Published:2013-08-01
  • Corresponding author: Fei-hai LING
  • About author:
    Corresponding author: LING Fei-hai, Email:
引用本文:

崔世恩, 凌飞海, 储兵. 不同亚型乳腺癌初次转移时间及带瘤生存的研究[J/OL]. 中华普通外科学文献(电子版), 2013, 07(04): 289-294.

Shi-en CUI, Fei-hai LING, Bing CHU. Studies on the distant relapse-free survival after relapse of different subtypes of breast cancer[J/OL]. Chinese Archives of General Surgery(Electronic Edition), 2013, 07(04): 289-294.

目的

分析不同亚型乳腺癌的转移出现时间及转移后生存时间的不同。

方法

1998年1月至2004年12月间在中山市人民医院接受手术的可手术、原发性浸润性乳腺癌的390例患者被入组本研究。依雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体2(HER2)表达情况将肿瘤分为luminal A、luminal B、HER2型和三阴性型共4种亚型。随访这些患者,记录初次远处转移出现时间及死亡时间。

结果

215例(55.1%)为luminal A型、80例(20.5%)是三阴性型、52例(13.3%)是HER2型、43例(11.0%)为luminal B型。中位随访时间为118个月。在术后的36个月内,luminal A型和luminal B型乳腺癌患者中分别出现了19例(8.8%)和2例(4.7%)远处转移;HER2型和三阴性型乳腺癌的转移率显著高于luminal型,分别为19.2%和20.0%(P < 0.05)。术后37~72个月间,4个亚型间的转移率差异无统计学意义。术后73~108个月间,luminal型乳腺癌的远处转移发生比例显著高于HER2型和三阴性型(P < 0.05)。从初次转移至死亡的中位存活时间luminal A型患者为28个月;luminal B型为22个月;HER2型为9个月;三阴性型为6个月(P < 0.05)。

结论

不同亚型乳腺癌的初次远处转移出现时间不同,转移后带瘤存活时间也不同。HER2型和三阴性型乳腺癌转移出现较早,转移出现后生存时间短,但术后5年后转移出现明显减少。luminal型肿瘤转移发生较晚,转移后带瘤存活时间长,但其在术后相当长的时间内始终存在转移可能。

Objective

To investigate the distant relapse-free survival, as well as survival after relapse, among different subtypes of breast cancer.

Methods

Patients with operable primary invasive breast cancer diagnosed in Zhongshan City People's Hospital from Jan. 1998 to Dec. 2004 were recruited. Subtypes were defined as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2) enriched, and triple negative (TN) according to the expression of Estrogen Receptor (ER), Progestogen Receptor (PR) and HER2 status. The time of the appearance of the first distant metastasis and death of patients were recorded.

Results

Two hundred and fifteen (55.1%) patients were luminal A, 43 (11.0%) were luminal B, 52 (13.3%) were HER2 enriched, and 80 (20.5%) were TN. The median follow-up time was 118 months. In the first three years after operation, 19 (8.8%) and 2 (4.7%) metastases occurred in patients with luminal A and luminal B type of breast cancer, respectively. Patients with HER2 (19.2%) and TN type (20.0%) of breast cancer had a significantly higher metastasis rate than those with luminal type of breast cancer (P < 0.05). There's no significant difference of metastasis rate among the four subgroups during 37 months to 72 months after operation. Patients with luminal types of breast cancer had a higher rate of metastasis than patients with other types of breast cancer in the period of 73 months to 108 months after operation (P < 0.05). Median durations of survival with distant metastasis were 28 months for luminal A, 22 for luminal B, 9 for HER2, and 6 for TN (P < 0.05), respectively.

Conclusions

The subtypes of breast cancer are associated with distinct patterns of metastatic spread with notable differences in survival after relapse. Patients with HER2 type or TN type of breast cancer develop metastasis earlier than patients with luminal type of breast cancer did. The duration of survival after metastasis is longer for patients with luminal type of breast cancer than patients with other types of breast cancer. However, for patients with luminal types of breast cancer, the chance of relapse always exist, even in a relatively long time after operation.

表1 各亚型乳腺癌术后3年、6年及9年后出现的远处转移事件数[例(%)]
表2 各亚型乳腺癌术后3年、6年及9年后出现的远处转移事件数(例)
图1 4种亚型乳腺癌患者术后9年的无远处转移生存率
图2 4种亚型乳腺癌患者术后9年时的总生存率
1
Spitale A, Mazzola P, Soldini D, et al. Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol, 2009, 20(4): 628-635.
2
Michael G, Nadia H, Christoph T. St. Gallen 2011: Summary of the Consensus Discussion. Breast Care (Basel), 2011, 6(2): 136-141.
3
Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature, 2000, 406(6797): 747-752.
4
骆成玉. 乳腺癌乳腔镜腋窝淋巴结清扫手术的临床实践与思考[J/CD]. 中华腔镜外科杂志:电子版, 2010, 3(1): 23-27.
5
邹菊,王松,梁庆模.乳腺癌新辅助化疗疗效的评价方法[J/CD].中华普通外科学文献:电子版, 2012, 6(1): 71-74.
6
Hugh J, Hanson J, Cheang MCU, et al. Breast cancer subtypes and response to docetaxel in node positive breast cancer; use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol, 2009, 27(8): 1168-1176.
7
Zaha DC, Lazar E, Lazureanu C. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol, 2010, 51(1): 85-89.
8
Sorlie T, Perou CM, Tibshirani R, et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 2001, 98(19): 10869-10874.
9
Kennecke HF, Olivotto IA, Speers C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol, 2007, 18(1): 45-51.
10
Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol, 2010, 28(20): 3271-3277.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[3] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[6] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[7] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[8] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[9] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[10] 刘郁, 段绍斌, 丁志翔, 史志涛. miR-34a-5p 在结肠癌患者的表达及其与临床特征及预后的相关性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 485-490.
[11] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[12] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[13] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[14] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[15] 王曦娅, 尹弘青, 丁伟, 徐滨, 于海源, 马东升, 邵军. 桥本背景下甲状腺乳头状癌多参数分析预测大容量淋巴结转移[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 548-554.
阅读次数
全文


摘要